Health tech company The cGP Lab has identified a gap in the market for type 2 diabetes support.
A clinical study completed through an organisational collaboration identified that people with type 2 diabetes found taking cyclic glycine-proline (cGP) orally for three months significantly reduced the
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
